Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1983 1
2005 1
2006 2
2007 5
2008 1
2009 2
2010 2
2011 2
2012 3
2013 3
2015 5
2016 8
2017 4
2018 2
2019 9
2020 12
2021 12
2022 11
2023 15
2024 16
2025 16
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Results by year

Filters applied: . Clear all
Page 1
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.
Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL, Aapro M, Dennis K, Hesketh PJ, Navari RM, Schwartzberg L, Affronti ML, Garcia-Del-Barrio MA, Chan A, Celio L, Chow R, Fleury M, Gralla RJ, Giusti R, Jahn F, Iihara H, Maranzano E, Radhakrishnan V, Saito M, Sayegh P, Bosnjak S, Zhang L, Lee J, Ostwal V, Smit T, Zilic A, Jordan K, Scotté F; participants of the MASCC/ESMO Consensus Conference 2022. Electronic address: clinicalguidelines@esmo.org. Herrstedt J, et al. Among authors: iihara h. ESMO Open. 2024 Feb;9(2):102195. doi: 10.1016/j.esmoop.2023.102195. Epub 2024 Jan 11. ESMO Open. 2024. PMID: 38458657 Free PMC article.
Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical Trial.
Abe M, Yamaguchi T, Fujita Y, Nishimura T, Kitagawa K, Inui N, Hirano K, Sakata Y, Iihara H, Shibuya Y, Suzuki K, Shibata K, Hori K, Daga H, Nakayama T, Sakata Y, Takahashi TY, Zenda S, Hashimoto H. Abe M, et al. Among authors: iihara h. JAMA Netw Open. 2023 May 1;6(5):e2310894. doi: 10.1001/jamanetworkopen.2023.10894. JAMA Netw Open. 2023. PMID: 37129897 Free PMC article. Clinical Trial.
Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial.
Saito M, Iihara H, Shimokawa M, Udagawa R, Tsuneizumi M, Futamura M, Ishikawa Y, Ogata H, Bando H, Shima H, Hosoya K, Mukohara T, Tanaka K, Ikuta T, Kawate T, Ishida K, Nakai K, Uomori T, Kutomi G, Ozeki R, Yanagisawa N. Saito M, et al. Among authors: iihara h. Lancet Oncol. 2025 Jul;26(7):960-970. doi: 10.1016/S1470-2045(25)00233-5. Epub 2025 Jun 18. Lancet Oncol. 2025. PMID: 40541214 Clinical Trial.
Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023.
Kobayashi M, Kako J, Iba A, Okuyama A, Ozawa K, Abe M, Wada M, Akechi T, Iihara H, Imamura CK, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Iino K. Kobayashi M, et al. Among authors: iihara h. Int J Clin Oncol. 2024 Jul;29(7):889-898. doi: 10.1007/s10147-024-02536-w. Epub 2024 May 9. Int J Clin Oncol. 2024. PMID: 38722486
The role of pharmacists in multimodal cancer cachexia care.
Fujii H, Yamada Y, Iihara H, Suzuki A. Fujii H, et al. Among authors: iihara h. Asia Pac J Oncol Nurs. 2023 Aug 1;10(Suppl 1):100280. doi: 10.1016/j.apjon.2023.100280. eCollection 2023 Nov. Asia Pac J Oncol Nurs. 2023. PMID: 38197038 Free PMC article. Review.
Chemotherapy-related hand-foot syndrome and hand-foot skin reaction: a review of management and possible approaches for Asian patients by the Japanese pharmacist-led oncodermatology study team.
Iimura Y, Iihara H, Saito Y, Nomura H, Iwamoto T, Kotera M, Tsuchiya Y, Sumiya T, Kono M, Hirate D, Kurokawa T, Hayashi T, Hashimoto H, Higuchi J, Urakawa R, Saotome H, Kuroda S; Japanese Pharmacist-led Oncodermatology Study Team (J-PLOS). Iimura Y, et al. Among authors: iihara h. Int J Clin Oncol. 2025 Dec;30(12):2474-2488. doi: 10.1007/s10147-025-02895-y. Epub 2025 Oct 6. Int J Clin Oncol. 2025. PMID: 41053386 Free PMC article.
123 results